MH & Associates Securities Management Corp ADV Buys Shares of 37,262 Gilead Sciences, Inc. $GILD

MH & Associates Securities Management Corp ADV bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 37,262 shares of the biopharmaceutical company’s stock, valued at approximately $4,574,000. Gilead Sciences accounts for approximately 3.7% of MH & Associates Securities Management Corp ADV’s portfolio, making the stock its 3rd biggest holding.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. Csenge Advisory Group lifted its position in shares of Gilead Sciences by 319.0% during the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock valued at $2,375,000 after acquiring an additional 16,288 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in shares of Gilead Sciences by 52.1% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after acquiring an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. lifted its position in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after acquiring an additional 7,168 shares during the period. Railway Pension Investments Ltd lifted its position in shares of Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after acquiring an additional 42,200 shares during the period. Finally, TriaGen Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter valued at approximately $1,274,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline — Gilead agreed to acquire Tubulis (up to $5B), adding next‑generation ADC technology and early‑stage cancer assets that expand its oncology capabilities and R&D footprint. Gilead to acquire Tubulis GmbH for up to $5 billion
• Positive Sentiment: Deals show strategic pivot and investor interest — This Tubulis purchase is the third takeout in weeks, reinforcing management’s pivot away from reliance on legacy franchises toward oncology and autoimmune opportunities; some desks (Needham, Bernstein, Leerink) highlight upside from the expanded pipeline. With 3 quick buyouts, Gilead leans into its latest transformation
• Neutral Sentiment: Earnings track record and guidance remain supportive — Gilead’s recent quarterly beat and FY‑2026 EPS guidance provide a stable fundamental backdrop that reduces downside risk and makes acquisition-driven upside more credible. Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
• Negative Sentiment: Execution and valuation concerns — Some analysts (Goldman Sachs) remain cautious, citing integration and execution risk from rapid M&A and the contingent milestone structure; a few firms keep Hold/neutral stances and conservative price targets that limit near‑term upside. Balancing Strategic Oncology Expansion and Execution Risk
• Negative Sentiment: Street price targets and coverage remain mixed — RBC and other shops have adjusted targets and maintained conservative/sector‑perform ratings despite the deal, reflecting differing views on how much value the Tubulis assets will deliver versus the purchase price. RBC adjusts price target on Gilead Sciences

Gilead Sciences Trading Up 2.0%

Shares of Gilead Sciences stock opened at $141.54 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The company has a market capitalization of $175.68 billion, a P/E ratio of 20.91, a P/E/G ratio of 1.83 and a beta of 0.39. The business has a 50 day moving average price of $145.13 and a 200 day moving average price of $130.09.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on GILD shares. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Citigroup reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, March 6th. Leerink Partners lifted their price target on Gilead Sciences from $146.00 to $148.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Argus lifted their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $157.81.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the completion of the transaction, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 299,280 shares of company stock worth $42,820,550. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.